Pharvaris shares experienced a volatile trading session early Monday after the FDA agreed to review a treatment for a serious swelling disease [1].

This development is critical because FDA review is the final regulatory hurdle before a biotech company can bring a new drug to the U.S. market. The outcome of this review will determine if the company can commercialize its treatment and generate new revenue streams.

Market activity showed significant swings throughout the day. Pharvaris stock jumped early Monday, but closed down [1]. This "yo-yo" effect reflects the high-risk nature of biotech investing, where positive regulatory news can trigger immediate buying followed by profit-taking.

Despite the volatility on Monday, the company has seen recent growth. Reports indicate the stock is up 14% [1] since its breakout. Other data points suggest an increase of 12% [1] since that same period.

The FDA's agreement to review the treatment marks a formal step in the New Drug Application process. The agency will now examine the clinical data to ensure the treatment is safe and effective for patients suffering from the swelling disease [1].

Investors are now monitoring the timeline for the FDA's final decision. Because the company's valuation is closely tied to this specific drug candidate, any further updates from regulators are expected to cause additional price swings [1].

“Pharvaris stock jumped early Monday, but closed down”

The volatility in Pharvaris stock highlights the binary nature of biotech valuations. While the FDA's agreement to review the treatment is a positive procedural step, it is not a guarantee of approval. The market's reaction suggests a tension between long-term optimism regarding the drug's potential and short-term caution regarding the rigorous FDA approval process.